| Carvone — Carvone is a chiral oxygenated monocyclic monoterpene ketone found mainly as enantiomeric forms in spearmint, caraway, dill, and related essential oils. It is best classified as a small-molecule natural product / volatile terpenoid flavor-fragrance compound, commonly abbreviated CRV. The biologically relevant forms are often reported as l-carvone, d-carvone, R-carvone, or S-carvone, but naming conventions are inconsistent across papers, so note the exact enantiomer stated by each source.
Primary mechanisms (ranked):
- Induction of cancer-cell apoptosis through p53, Bad, caspase-3 activation, PARP cleavage, and DNA-damage-associated stress signaling.
- Suppression of migration, adhesion, invasion, and metastatic behavior, especially through FAK-related signaling in breast cancer models.
- Context-dependent oxidative stress modulation, including ROS increase and DNA damage at cytotoxic in-vitro concentrations.
- Inhibition of proliferative survival pathways, including JAK/STAT3 in gastric cancer and p38 MAPK-related signaling in myeloma models.
- Cell-cycle disruption, reported as S-phase, G0/G1, or G2/M arrest depending on enantiomer, cancer model, and concentration.
- Possible chemopreventive activity in animal skin-carcinogenesis models, but not established as a clinically validated anticancer agent.
Bioavailability / PK relevance: Carvone is lipophilic and volatile, with oral, dermal, and inhalational exposure relevance depending on formulation. Human PK/metabolism data exist for ingestion-correlated and topical/percutaneous exposure contexts, but anticancer studies generally use concentrations that are not directly matched to validated systemic anticancer exposure. Essential-oil delivery introduces variability from enantiomer ratio, co-terpenes, oxidation products, and formulation.
In-vitro vs systemic exposure relevance: Common anticancer in-vitro effects occur at high micromolar to millimolar or microgram-per-millilitre ranges, and breast-cancer IC50 values around the millimolar range have been reported. These levels are likely above ordinary dietary flavor exposure and may exceed practical systemic exposure from food-like intake. Interpretation should therefore be concentration-constrained and formulation-dependent.
Clinical evidence status: Preclinical for cancer. Evidence includes cancer cell-line studies, animal chemoprevention/tumor models, and mechanistic studies, but no credible cancer RCTs of carvone as a therapeutic agent were identified. Human studies involving carvone-containing preparations exist for non-cancer indications or mixtures, but they should not be treated as direct anticancer evidence for isolated carvone.
Safety / regulatory status: Carvone is listed as a FEMA GRAS flavoring substance with CFR flavor-use reference, but this applies to intended flavor-use exposure, not therapeutic dosing. Major constraints include skin sensitization potential, enantiomer/formulation variability, volatile exposure, and uncertain safety at high supplemental or pharmacologic doses. Fragrance safety assessment data indicate no genotoxic concern under reviewed conditions, but l-carvone is considered a skin sensitizer.
Carvone Mechanistic Profile
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Apoptosis execution |
↑ p53, ↑ Bad, ↑ cleaved caspase-3, ↑ cleaved PARP |
Lower sensitivity reported in some normal-cell comparisons |
G |
Pro-apoptotic cytotoxicity |
Most central anticancer mechanism; strongest evidence is in vitro and concentration-dependent. |
| 2 |
Migration adhesion invasion |
↓ migration, ↓ adhesion, ↓ invasion, ↓ FAK activation |
Not well-defined |
G |
Anti-metastatic phenotype |
Mechanistically important for breast cancer models; therapeutic leverage is plausible but not clinically validated. |
| 3 |
ROS and DNA damage stress |
↑ ROS, ↑ DNA damage markers, ↑ apoptotic stress |
Context-dependent antioxidant or cytoprotective effects reported outside cancer |
R/G |
Stress-mediated apoptosis |
ROS appears pro-apoptotic in several cancer contexts; antioxidant effects in non-cancer models make this axis context-dependent. |
| 4 |
JAK STAT3 survival signaling |
↓ JAK/STAT3 signaling in gastric cancer models |
Not well-defined |
G |
Reduced survival signaling |
Promising but model-specific; should not be generalized across all tumor types without direct evidence. |
| 5 |
p38 MAPK signaling |
↓ p38 MAPK-related signaling in myeloma models |
Not well-defined |
G |
Growth and invasion suppression |
Reported in myeloma; secondary/contextual relative to apoptosis and motility effects. |
| 6 |
Cell cycle control |
↑ arrest at S, G0/G1, or G2/M depending on model |
Not well-defined |
G |
Reduced proliferation |
Direction of arrest is inconsistent across cancer systems and enantiomer reports; keep model-specific. |
| 7 |
Mitochondrial apoptosis |
↓ mitochondrial membrane potential reported in some models, ↑ caspase-linked apoptosis |
Context-dependent |
R/G |
Intrinsic apoptosis support |
Relevant when mitochondrial depolarization or ROS-mediated apoptosis is directly measured. |
| 8 |
Angiogenesis tumor microenvironment |
↓ angiogenesis stimulus in Ehrlich tumor context |
Not well-defined |
G |
Reduced tumor support phenotype |
Evidence is less mature than direct cancer-cell apoptosis and migration data. |
| 9 |
NRF2 redox adaptation |
↔ or uncertain |
Possible cytoprotective relevance in oxidative stress models |
G |
Unresolved redox adaptation |
|
| 10 |
Clinical Translation Constraint |
High in-vitro concentrations may not map to achievable systemic exposure |
Skin sensitization and exposure-route constraints |
G |
Limits translational confidence |
Bioavailability, enantiomer identity, essential-oil composition, and flavor-use versus therapeutic-dose safety are the main constraints. |
P: 0–30 min R: 30 min–3 hr G: >3 hr
|